Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.7852W HIGH $43.73
Volume
3.64 M
Value Traded
66.66 M
Short % Float
11.63%
-3.03%Week
-12%1 Month
-22.61%3 Month
-17.29%6 Month
+281.66%5 Year
-30.49%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.22 B
EPS (TTM)
-2.17
P/E Ratio
-
Ent. Value
4.65 B
Total Shares
173.59 M
Float Shares
155.83 M
Insiders
10.22%
Institutions
103.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
COGT Catalyst Timeline
Dated clinical, regulatory and corporate events for Cogent Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cogent Biosciences, Inc.
385Total events
11Upcoming
75Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲FDA Filing AcceptedBezuclastinibFiledRegulatory Filing
FDA accepts NDA for bezuclastinib in AdvSM
Advanced Systemic Mastocytosis (AdvSM)source ↗
▲AdCom CancelledBezuclastinibFiledAdvisory Committee
FDA communicated no plan to hold an advisory committee for bezuclastinib AdvSM NDA
Advanced Systemic Mastocytosis (AdvSM)source ↗
▼ATM ProgramCorporate
Raised $73.6 million gross proceeds from ATM facility after quarter end
◆Poster PresentationCGT1145Presentation
Poster presentation on preclinical characterization of CGT1145 at EHA 2026
JAK2 V617F mutant-selective inhibitorsource ↗
◆Poster PresentationBezuclastinibFiledPresentation
Poster presentation on pathobiology results from APEX trial at EHA 2026
Advanced Systemic Mastocytosissource ↗
▲Oral PresentationBezuclastinibFiledPresentation
Detailed data from APEX pivotal trial presented at EHA 2026
advanced systemic mastocytosissource ↗
●Timing GuidanceBezuclastinibFiledPresentation
APEX NDA to be submitted in June 2026
advanced systemic mastocytosissource ↗
●Trial InitiationBezuclastinibFiledTrial
Phase 2 trial initiation for first-line GIST with exon 9 mutations expected mid-2026
GIST with exon 9 mutations (first-line)source ↗
▲Oral PresentationBezuclastinibFiledPresentation
Primary Results of the Phase 3 PEAK Study of Bezuclastinib + Sunitinib vs Sunitinib Monotherapy in Advanced GIST presented at ASCO 2026
Gastrointestinal Stromal Tumors (GIST)source ↗
▲Trial InitiationBezuclastinibFiledTrial
Initiation of new clinical trial of bezuclastinib combination in 1L GIST patients with KIT exon 9 mutations
Gastrointestinal Stromal Tumors (GIST)source ↗
▲FDA Filing AcceptedBezuclastinibFiledRegulatory Filing
FDA accepts NDA for bezuclastinib + sunitinib with Priority Review
Gastrointestinal Stromal Tumors (GIST)source ↗
▲Priority ReviewBezuclastinibFiledRegulatory Filing
Priority Review granted for bezuclastinib NDA
Gastrointestinal Stromal Tumors (GIST)source ↗
▲AdCom CancelledBezuclastinibFiledAdvisory Committee
FDA communicated no plan to hold an advisory committee
Gastrointestinal Stromal Tumors (GIST)source ↗
▲Priority ReviewBezuclastinibFiledRegulatory Filing
FDA granted Priority Review for NDA of bezuclastinib combination in GIST patients who previously received imatinib
Gastrointestinal Stromal Tumors (GIST)source ↗
●Poster PresentationCGT4255Presentation
Poster presentation on CGT4255 at AACR 2026
HER2+ cancers with brain metastasessource ↗
●Poster PresentationCGT1263Presentation
Poster presentation on CGT1263 at AACR 2026
KRAS-mutant cancerssource ↗
●Timing GuidanceBezuclastinibFiledPresentation
NDA submission for bezuclastinib under RTOR on track for April 2026
Gastrointestinal Stromal Tumors (GIST)source ↗
▲FDA Filing AcceptedBezuclastinibFiledRegulatory Filing
FDA accepted NDA for bezuclastinib in NonAdvSM
NonAdvanced Systemic Mastocytosis (NonAdvSM)source ↗
▲AdCom CancelledBezuclastinibFiledAdvisory Committee
FDA communicated no plan to hold advisory committee for bezuclastinib NDA
NonAdvanced Systemic Mastocytosis (NonAdvSM)source ↗
●NDA SubmissionBezuclastinibFiledRegulatory Filing
NDA submitted under RTOR program
Gastrointestinal Stromal Tumors (GIST)source ↗
▲Poster PresentationBezuclastinibFiledPresentation
Additional clinical results from SUMMIT trial presented at AAAAI 2026
NonAdvanced Systemic Mastocytosissource ↗
●NDA SubmissionBezuclastinibFiledRegulatory Filing
PEAK NDA initiated under RTOR for bezuclastinib in second-line GIST
second-line GISTsource ↗
▲Timing GuidanceBezuclastinibFiledPresentation
FDA acceptance of NDA for bezuclastinib in NonAdvSM expected by end of February 2026
NonAdvanced Systemic Mastocytosissource ↗
▲Breakthrough Therapy DesignationBezuclastinibFiledDesignation
FDA granted Breakthrough Therapy Designation for bezuclastinib in combination with sunitinib for GIST
Gastrointestinal Stromal Tumors (GIST)source ↗
▲FDA Filing AcceptedBezuclastinibFiledRegulatory Filing
FDA agrees to accept NDA for bezuclastinib plus sunitinib under RTOR
Gastrointestinal Stromal Tumors (GIST)source ↗
▲Breakthrough Therapy DesignationBezuclastinibFiledDesignation
Breakthrough Therapy Designation granted for bezuclastinib in GIST
Gastrointestinal Stromal Tumors (GIST)source ↗
◆Full ResultsBezuclastinibFiledClinical Data
Full PEAK trial results to be presented at major medical meeting in H1 2026
Gastrointestinal Stromal Tumors (GIST)source ↗
▲Oral PresentationBezuclastinibFiledPresentation
Presented detailed clinical data from Phase 3 PEAK trial at ASCO 2026
GISTsource ↗
▲FDA Filing AcceptedBezuclastinibFiledRegulatory Filing
FDA accepted NDA for bezuclastinib in NonAdvSM
NonAdvanced Systemic Mastocytosis (NonAdvSM)source ↗
▲Trial InitiationCGT4255Trial
Phase 1 study initiated for CGT4255, a novel selective brain-penetrant ErbB2 inhibitor
ErbB2 mutant cancerssource ↗
▲Trial InitiationCGT6297Trial
Phase 1 study initiated for CGT6297, a novel selective PI3K inhibitor
PI3K mutant cancerssource ↗
▲Topline ReadoutBezuclastinibFiledClinical Data
APEX pivotal trial results presented at 2026 EHA Congress
Advanced Systemic Mastocytosis (AdvSM)source ↗
●NDA SubmissionBezuclastinibFiledRegulatory Filing
NDA submission for bezuclastinib in NonAdvSM
NonAdvanced Systemic Mastocytosissource ↗
▲Oral PresentationBezuclastinibFiledPresentation
Preliminary 48-week data shared during investor call
nonadvanced systemic mastocytosissource ↗
▲Topline ReadoutBezuclastinibFiledClinical Data
Positive top-line results from APEX Part 2 trial of bezuclastinib in AdvSM
advanced systemic mastocytosis (AdvSM)source ↗
▲Full ResultsBezuclastinibFiledClinical Data
Full SUMMIT Part 2 results presented at ASH 2025
nonadvanced systemic mastocytosissource ↗
◆Poster PresentationCGT1145Presentation
Poster presentation on novel JAK2 V617F mutant-selective inhibitor at ASH 2025
Myeloproliferative Neoplasmssource ↗
▲Full ResultsBezuclastinibFiledClinical Data
Full SUMMIT Part 2 results presented at ASH 2025
NonAdvSMsource ↗
Past FDA Catalysts and PDUFA Decisions
How COGT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | Bezuclastinib | NDA Submission | NDA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C49 / 100
Pipeline Score
$575M
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 19%
Small Cap(rank 126 of 658)
Percentile Rank
Cogent Biosciences, Inc. carries a moderate pipeline score (49/100), with $885M risk-adjusted pipeline value, led by Bezuclastinib in Gastrointestinal Stromal Tumors (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bezuclastinib Small moleculeNCT05208047 | Advanced Gastrointestinal Stromal Tumors | Phase 3 | RECRUITING | 482 | Jan 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every COGT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| bezuclastinib BreakthroughPriority | advanced systemic mastocytosis | 2026-06-12 | 65% objective response rate; 81% ORR per PPR criteria; 91% of patients achieving ≥50% reduction in variant allele frequency; 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates; 12-month PFS rate of 79%; 12-month OS rate of 87%Read More | Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) CongressRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Morris ArleneDirector | Option | 41,927 41,927 held | $5.64 | 08/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in COGT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 14.1 % (-7.8 %) | 212.98 M | 5.50 M |
COGT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How COGT ranks across every disease it competes in
Competitive Position is a premium feature
See how COGT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCOGT News
COGTCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences announced that the FDA has accepted its New Drug Application for bezuclastinib, aimed at treating Advanced Systemic Mastocytosis (AdvSM). The acceptance is backed by positive results from the APEX trial, which showed a 65% overall response rate. The PDUFA target action date is set for June 29, 2027, with no advisory committee planned.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences reported positive developments including the potential FDA approval of bezuclastinib for GIST and NonAdvSM patients by the end of 2026. The company has successfully onboarded a skilled customer-facing team and maintains a robust cash position to support operations. However, it also reported a significant net loss and rising R&D expenses.
Read more →COGTCogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences has submitted a New Drug Application for bezuclastinib to the FDA for treating Advanced Systemic Mastocytosis. The submission is based on positive results from the APEX pivotal trial, which demonstrated a 65% objective response rate and a well-tolerated safety profile. The company is optimistic about achieving FDA approval by Q4 2026.
Read more →COGTCogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences presented promising preclinical data for its JAK2 V617F inhibitor, CGT1145, at the 2026 EHA Congress. The drug exhibits high selectivity and oral bioavailability, potentially addressing key disease drivers in myeloproliferative neoplasms. The company aims to submit an Investigational New Drug application in 2026.
Read more →COGTCogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences presented updated results from the APEX trial of bezuclastinib for advanced systemic mastocytosis at the 2026 EHA Congress. The trial demonstrated a 65% objective response rate and significant reductions in mast cell burden. The drug also showed a favorable safety profile. An NDA submission is planned for June 2026.
Read more →COGTCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences announced promising results from the PEAK Phase 3 trial, demonstrating that the bezuclastinib and sunitinib combination significantly improves progression-free survival in GIST patients compared to sunitinib alone. The combination therapy was well tolerated, with no new risks identified. The FDA has granted Priority Review for this treatment, with a PDUFA date set for November 30, 2026.
Read more →COGTCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
Cogent Biosciences has announced the FDA's acceptance of its New Drug Application for bezuclastinib in combination with sunitinib for treating GIST patients. The application has been granted Priority Review, with a target action date set for November 30, 2026. The combination therapy demonstrated a significant improvement in median progression-free survival compared to sunitinib alone, marking a potential breakthrough in treatment options.
Read more →COGTCogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
Cogent Biosciences, Inc. will participate in the Jefferies Global Healthcare Conference on June 3, 2026. The event will feature a live webcast accessible via the company's website. Additionally, Cogent announced inducement equity awards for new employees, reflecting its commitment to growth and innovation in precision therapies for genetically defined diseases.
Read more →COGTCogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
Cogent Biosciences has announced two key presentations at the upcoming European Hematology Association Congress 2026. The company will present pivotal data from its APEX trial on bezuclastinib, a therapy for Advanced Systemic Mastocytosis, showcasing its findings in two oral sessions. Additionally, preclinical data from their selective JAK2 V617F program will be highlighted in a poster presentation. These presentations represent a significant platform for Cogent to share its advancements in targeted therapies at an esteemed international venue.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences has reported significant business highlights and financial results for Q1 2026, including plans for dual launches of their drug bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors. The company has a strong financial position, ending the quarter with $866.4 million in cash, which is expected to fund operations into 2028. The upcoming ASCO annual meeting will feature pivotal data from the Phase 3 PEAK trial, potentially setting the stage for multiple drug launches. However, the company recorded a larger net loss this quarter compared to the previous year, alongside increased R&D expenses.
Read more →COGTCogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences announced that results from its Phase 3 PEAK trial will be presented at the 2026 ASCO Annual Meeting. The trial demonstrated positive outcomes for bezuclastinib combined with sunitinib in GIST patients previously treated with imatinib. The company is also set to initiate a Phase 2 trial for first-line GIST patients with exon 9 mutations.
Read more →COGTCogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Cogent Biosciences announced the presentation of preclinical data on its KRAS and ErbB2 pipeline programs at the AACR Annual Meeting 2026. The data highlights CGT1263's selectivity and potential to reduce skin toxicity, while CGT4255 shows promise in combination with HER2 ADCs for resistant patients. The company is preparing for the potential launch of bezuclastinib later this year.
Read more →COGT▼ -8.4%on this news
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences has submitted a New Drug Application for bezuclastinib to the FDA for treating gastrointestinal stromal tumors (GIST) in patients previously treated with imatinib. The submission is based on positive results from the Phase 3 PEAK trial, which showed a significant increase in progression-free survival and response rates compared to existing treatments. The company aims to present full trial results at a major medical meeting in 2026.
Read more →COGTCogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Cogent Biosciences has announced the FDA's acceptance of its New Drug Application for bezuclastinib, targeting patients with NonAdvanced Systemic Mastocytosis. The FDA set a target action date of December 30, 2026, and plans to avoid an advisory committee meeting. Clinical trial results indicated significant improvements across primary and secondary endpoints, showcasing bezuclastinib's efficacy and safety profile. The company is also on track to submit additional NDA applications for bezuclastinib in related indications in the near future.
Read more →COGTCogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
Cogent Biosciences presented additional data from the SUMMIT trial at the AAAAI Annual Meeting, highlighting the efficacy of bezuclastinib in treating NonAdvanced Systemic Mastocytosis. The results showed significant improvements across primary and secondary endpoints, reinforcing the drug's potential as a preferred treatment option. The findings also indicated benefits in bone mineral density, suggesting disease modification.
Read more →COGTCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences reported strong business highlights and financial results for 2025, showcasing momentum with three successful pivotal trials. The company is advancing its lead product, bezuclastinib, with multiple NDA submissions planned for 2026. Despite a net loss of $102.5 million in Q4 2025, Cogent maintains a robust cash position of $900.8 million.
Read more →COGTCogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
Cogent Biosciences announced that it will present multiple posters at the 2026 AAAAI Annual Meeting, focusing on bezuclastinib results from the SUMMIT trial in patients with NonAdvanced Systemic Mastocytosis. The company has submitted a New Drug Application for bezuclastinib based on positive clinical data and previously received Breakthrough Therapy Designation. The presentations will take place on February 28, 2026.
Read more →COGTCogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences has received Breakthrough Therapy Designation from the FDA for bezuclastinib combined with sunitinib for treating imatinib-resistant GIST. The designation is based on promising results from the PEAK trial, showing a 50% reduction in disease progression risk. Cogent plans to submit its NDA by April 2026 and present full trial results at a major medical meeting.
Read more →COGTCogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences has received Breakthrough Therapy Designation from the FDA for its drug bezuclastinib in combination with sunitinib for treating gastrointestinal stromal tumors (GIST) in patients resistant to imatinib. The designation is based on promising results from the PEAK trial, showing a 50% reduction in disease progression risk. The company plans to submit its New Drug Application by April 2026 and present full trial results at a major medical meeting.
Read more →About Cogent Biosciences, Inc.
Headquarters180 THIRD AVENUE, WALTHAM, MA
BIOPHARMAWATCH ELITE PLUS
Trade the next COGT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime